GutCode › Akkermansia muciniphila Guide
Akkermansia muciniphila Degrades the Mucus Layer of Your Gut — and That Is Exactly Why It Is Protective: By Consuming Mucin, It Stimulates the Colon to Regenerate Thicker Mucus, Reinforce the Epithelial Barrier, and Reduce Endotoxin Translocation — Making This "Mucus-Eater" the Central Bacterium in Gut Barrier Integrity and Metabolic Health
Quick Answer
Akkermansia muciniphila is a mucin-degrading gut bacterium making up 3–7% of a healthy microbiome and depleted in obesity, diabetes, and IBD — and its pasteurized form actually outperforms live bacteria at improving metabolic health.
- •3–7% of a healthy microbiome; lower in metabolic disease
- •Everard 2013 (PNAS): reversed diet-induced obesity in mice
- •Plovier 2017 (Nature Medicine): pasteurized > live; Amuc_1100 is the key protein
- •Approved as an EU novel food in 2023
Updated: June 2026Akkermansia muciniphila · Akkermansia · Akkermansia supplement · Akkermansia probiotic · Akkermansia gut bacteria · what is Akkermansia muciniphila · Akkermansia gut barrier · Akkermansia mucin · Akkermansia mucus layer · Akkermansia gut health · Akkermansia obesity · Akkermansia diabetes · Akkermansia metabolic health · Akkermansia insulin resistance · Akkermansia insulin sensitivity · Akkermansia weight loss · Akkermansia blood sugar · Akkermansia gut microbiome · Akkermansia microbiota · Akkermansia abundance · normal Akkermansia levels · low Akkermansia · how to increase Akkermansia · increase Akkermansia naturally · Akkermansia food · Akkermansia diet · Akkermansia polyphenols · polyphenols Akkermansia · cranberry Akkermansia · pomegranate Akkermansia · resveratrol Akkermansia · grape polyphenols Akkermansia · Akkermansia omega-3 · fish oil Akkermansia · EPA DHA Akkermansia · Akkermansia fasting · intermittent fasting Akkermansia · caloric restriction Akkermansia · Akkermansia prebiotic · Akkermansia inulin · Akkermansia fiber · Akkermansia FOS · prebiotic for Akkermansia · mucin prebiotic · pasteurized Akkermansia · pasteurized vs live Akkermansia · Plovier 2017 · Plovier 2017 Akkermansia · Nature Medicine Akkermansia · Amuc_1100 · Amuc_1100 protein · Akkermansia outer membrane protein · Akkermansia active compound · Akkermansia bioactive · Everard 2013 · Everard 2013 Akkermansia PNAS · Akkermansia PNAS · Akkermansia obesity reversal · Akkermansia Cani · Patrice Cani Akkermansia · Akkermansia Belgium · Liege Akkermansia · UCLouvain Akkermansia · Akkermansia leaky gut · Akkermansia tight junctions · Akkermansia ZO-1 · Akkermansia claudin-3 · Akkermansia endotoxin · Akkermansia LPS · Akkermansia lipopolysaccharide · Akkermansia inflammation · Akkermansia anti-inflammatory · Akkermansia GLP-1 · Akkermansia peptide YY · Akkermansia satiety · Akkermansia verrucomicrobia · Akkermansia phylum · Verrucomicrobia gut · Akkermansia 16S rRNA · Akkermansia next generation sequencing · Akkermansia gut test · Akkermansia stool test · Akkermansia microbiome test · Akkermansia IBD · Akkermansia Crohn's disease · Akkermansia ulcerative colitis · Akkermansia colorectal cancer · Akkermansia immunotherapy · Akkermansia checkpoint inhibitor · Akkermansia cancer response · Akkermansia metformin · metformin Akkermansia mechanism · Akkermansia EU novel food · Akkermansia approved supplement · Akkermansia Pendlebury 2022 · Akkermansia clinical trial · Akkermansia human · WBF-010 Akkermansia
Akkermansia muciniphila is the founding member of the phylum Verrucomicrobia in the human gut — a distinct bacterial lineage separate from the dominant Firmicutes and Bacteroidetes that make up the majority of the microbiome. It was first isolated and characterized by Muriel Derrien, Willem de Vos, and colleagues at Wageningen University in 2004, and named for Antoon Akkermans, a Dutch microbiologist. A. muciniphila is an obligate anaerobe (dies in oxygen) and a specialist — it exclusively colonizes the mucus layer of the colon (mucosal niche) and uses mucin (the glycoprotein that forms the mucus gel) as its primary carbon and nitrogen source.
The apparent paradox — that a bacterium that degrades the protective mucus layer is beneficial to gut barrier health — resolves through understanding mucus biology: the mucus layer is not static. It is continuously synthesized and degraded; goblet cells (specialized intestinal epithelial cells) continuously secrete new mucin. When A. muciniphila degrades mucin, it removes old, cross-linked mucin and generates short-chain fatty acids (propionate in particular) from the fermentation of mucin sugars. These propionate signals and the physical stimulus of mucus degradation both stimulate goblet cells to secrete more mucin and proliferate. The net result: higher A. muciniphila abundance → more mucin turnover → thicker, more protective mucus layer — the opposite of what naive "bacteria eating your mucus" intuition would suggest.
3–7%
healthy microbiome abundance — in healthy lean adults, A. muciniphila typically represents 3–7% of the total gut microbiome (by 16S rRNA sequencing); it is consistently lower in: obese individuals (~1–2%); type 2 diabetic patients (~0.5–1%); inflammatory bowel disease patients (Crohn's and UC); colorectal cancer patients; cardiovascular disease patients; aging (abundance declines progressively after age 50 in most cohort studies); the inverse association between A. muciniphila abundance and metabolic disease risk is one of the most consistently replicated findings in microbiome research; however, causation vs correlation remains debated — the mouse evidence (Everard 2013) is the strongest causal argument; the human association data is extensive but does not definitively prove that low Akkermansia causes metabolic disease (vs metabolic disease causing low Akkermansia through altered gut environment); Everard 2013 (PNAS, Patrice Cani group, UCLouvain): mice fed high-fat diet to induce obesity were simultaneously administered A. muciniphila by gavage; result: Akkermansia treatment reversed multiple obesity-related phenotypes — reduced fat mass, reduced metabolic endotoxemia (lower serum LPS), improved insulin sensitivity, increased expression of tight junction proteins (ZO-1, claudin-3) in the intestinal epithelium; increased production of the endocannabinoid 2-arachidonoylglycerol (2-AG) — an endogenous molecule with both appetite-regulating and barrier-protective properties; this paper established Akkermansia as a primary mechanistic candidate in gut barrier-metabolic health crosstalk
Plovier 2017
pasteurized outperforms live — Plovier et al. 2017 (Nature Medicine): one of the most unexpected findings in microbiome science; when A. muciniphila was heat-killed (pasteurized at 70°C for 30 minutes) before administration to obese mice, the pasteurized bacteria produced superior metabolic outcomes compared to live bacteria; specifically: pasteurized Akkermansia showed greater improvement in insulin sensitivity, fat mass, and gut barrier integrity than live Akkermansia — while both outperformed the control group; the explanation: the outer membrane of A. muciniphila contains a specific protein — Amuc_1100 — that is a key mediator of the metabolic benefits; Amuc_1100 is a pili-like protein that activates Toll-like receptor 2 (TLR2) on intestinal epithelial cells → downstream tight junction reinforcement and anti-inflammatory signaling; in live bacteria, other bacterial components may partially antagonize or compete with Amuc_1100 activity; in pasteurized bacteria, Amuc_1100 is stable, exposed, and constitutively active without competing signals; additionally: pasteurized Akkermansia is far more stable for manufacturing and storage — it can survive room temperature, shipping, and stomach acid conditions that immediately kill live Akkermansia; Amuc_1100 recombinant protein: when Amuc_1100 protein alone was administered (without any bacterial cells), it reproduced the metabolic benefits — confirming Amuc_1100 as the primary bioactive molecule; the practical implication: commercial Akkermansia supplements use pasteurized bacteria, not live cultures — which is actually the correct formulation based on the evidence
Pendlebury 2022
first human RCT — the Pendlebury et al. 2022 (Nature Medicine) trial was the first randomized controlled trial of pasteurized A. muciniphila supplementation in humans; N=32 overweight/obese adults with metabolic syndrome; 3-month double-blind RCT; three arms: pasteurized Akkermansia (10¹⁰ cells/day), live Akkermansia (10¹⁰ cells/day), or placebo; primary outcomes: insulin resistance (HOMA-IR) and safety; results for pasteurized Akkermansia vs placebo: statistically significant reduction in insulin resistance (HOMA-IR); significant reduction in serum total cholesterol and LDL; trending reduction in liver inflammation markers; improved gut permeability markers; live Akkermansia: numerically improved in all categories but did not reach statistical significance (consistent with Plovier 2017 mouse data); safety: both forms were safe and well-tolerated across 3 months; no serious adverse events; the sample size (N=32) was small and the trial duration (3 months) was short — these are the primary limitations; follow-up larger trials are needed; the EU approval: in 2023, the European Food Safety Authority (EFSA) approved pasteurized A. muciniphila as a Novel Food ingredient — the first gut bacterium approved as a food supplement in the EU; this paved the way for commercial pasteurized Akkermansia supplements; metformin and Akkermansia: an interesting intersection — metformin (the first-line T2D drug) increases A. muciniphila abundance in both mice and humans; some researchers hypothesize that part of metformin's metabolic benefit is mediated by its effect on Akkermansia abundance — a gut-dependent mechanism supplementing its direct AMPK activation
Natural Boosters
how to increase Akkermansia without supplementing — several dietary and lifestyle factors robustly increase A. muciniphila abundance: POLYPHENOLS (strongest evidence): dietary polyphenols reach the colon largely unabsorbed and are preferentially metabolized by A. muciniphila; cranberry extract: Anhe et al. 2015 (J Nutr Biochem): cranberry polyphenol extract increased A. muciniphila 100-fold in obese mice; the polyphenol-A. muciniphila relationship is the most consistently replicated dietary finding; other polyphenol sources that increase Akkermansia: pomegranate (ellagitannins → urolithin A, which A. muciniphila metabolizes); grape/red wine polyphenols (resveratrol, quercetin); green tea (EGCG); apple (phloretin, quercetin); OMEGA-3 FATTY ACIDS: EPA + DHA administration increases A. muciniphila in multiple mouse and human studies; mechanism: omega-3s alter the fatty acid composition of the mucus layer, making it a more favorable substrate for A. muciniphila colonization; CALORIC RESTRICTION / INTERMITTENT FASTING: caloric restriction dramatically increases A. muciniphila in mice; in humans, Ramadan fasting models consistently show Akkermansia increase; INULIN / PREBIOTIC FIBER: while A. muciniphila primarily consumes mucin, it also ferments some prebiotic fibers; inulin and FOS supplementation increases Akkermansia modestly; the mucin production stimulated by prebiotics (via Bifidobacterium fermentation) may indirectly support A. muciniphila; AVOID: high-fat Western diet, artificial sweeteners (saccharin, aspartame), chronic antibiotics — all reduce Akkermansia abundance
Ready to fix this at the root?
The 30-Day Gut Reset is the full day-by-day protocol — mechanisms, dosed repair steps, a diagnostic chapter, food/swap tables, and a maintenance plan, built from the same research on this page.
Get the Gut Reset → $19
Interventions That Affect Akkermansia Abundance
| Intervention | Effect on Akkermansia | Evidence Level | Proposed Mechanism |
|---|
| Pasteurized Akkermansia supplement | Direct supplementation; 10¹⁰ cells/day | Human RCT (Pendlebury 2022): insulin resistance, cholesterol | Amuc_1100 → TLR2 → tight junction reinforcement |
| Polyphenols (cranberry, pomegranate) | Strong increase (up to 100× in mouse studies) | Mouse: strong; Human: emerging RCTs | Polyphenols are preferential A. muciniphila substrate in colon |
| Omega-3 EPA/DHA | Moderate increase | Mouse + human observational | Altered mucus fatty acid composition favors colonization |
| Caloric restriction / IF | Strong increase in mice; moderate in humans | Mouse: strong; Human: Ramadan models | Altered gut environment; reduced competing bacteria |
| Metformin | Consistent increase in T2D patients | Human: multiple cohorts | Unknown; possibly altered gut pH or bile composition |
| High-fat Western diet | Strong decrease | Mouse: causal; Human: observational | Altered mucus composition; increased competing pathogens |
| Antibiotics (broad-spectrum) | Strong decrease; slow recovery | Human: well-documented | Direct bactericidal; ecological disruption of mucosal niche |
Akkermansia Optimization Protocol
Supplementation (if choosing direct approach): pasteurized A. muciniphila 10¹⁰ CFU (or cells)/day is the dose used in Pendlebury 2022; available commercially under brand names including Pendulum Glucose Control (includes Akkermansia in a multi-strain formula) and pure pasteurized Akkermansia products from specialized microbiome supplement companies; take on an empty stomach or with a small meal; storage: unlike live probiotics, pasteurized Akkermansia does not require refrigeration — a key product advantage; typical supplementation duration in the RCT: 3 months; whether indefinite supplementation is needed or whether Akkermansia "establishes" in the gut is unknown from current human data.
Dietary approach (increase endogenous Akkermansia): DAILY polyphenol load: aim for 2–3 polyphenol-dense foods per day: berries (blueberry, cranberry, strawberry), pomegranate juice or seeds, dark chocolate (70%+), green tea (2–3 cups/day), red grapes or resveratrol-containing wine (moderate); the combination of different polyphenol classes appears additive; OMEGA-3: 2–3 servings of fatty fish weekly OR EPA/DHA supplement 2g/day; AVOID top Akkermansia antagonists: processed/fast food high-fat diet; artificial sweeteners in diet sodas and protein bars (saccharin and aspartame both significantly reduce Akkermansia); unnecessary antibiotic use; PREBIOTIC SUPPORT: 5–10g inulin or FOS/day creates a gut environment that modestly favors Akkermansia; the fiber-Bifidobacterium-mucin-Akkermansia positive feedback loop is one reason diverse prebiotic fiber intake supports overall gut barrier integrity.
Context for immune checkpoint therapy: an emerging and important clinical application — Routy et al. 2018 (Science): non-small cell lung cancer patients on antibiotic therapy (which suppresses Akkermansia) had significantly worse outcomes on PD-1/PD-L1 checkpoint inhibitor immunotherapy; fecal microbiota transfers from responders (high Akkermansia) to germ-free mice improved checkpoint response; this has opened clinical trials of microbiome modulation as a checkpoint therapy enhancer; for cancer patients specifically undergoing immunotherapy, Akkermansia optimization may be clinically meaningful — discuss with oncologist.
Pasteurized Akkermansia →
Cranberry Polyphenols →
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.